$100.42
0.20% yesterday
Nasdaq, Sep 03, 10:04 pm CET
ISIN
US09075V1026
Symbol
BNTX

BioNTech SE - ADR Stock price

$100.42
-9.61 8.73% 1M
-11.14 9.99% 6M
-13.53 11.87% YTD
+12.42 14.11% 1Y
-47.48 32.10% 3Y
+41.92 71.67% 5Y
+86.37 614.63% 10Y
+86.37 614.63% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.20 0.20%
ISIN
US09075V1026
Symbol
BNTX
Industry

Key metrics

Basic
Market capitalization
$24.0b
Enterprise Value
$8.0b
Net debt
positive
Cash
$16.4b
Shares outstanding
240.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.2 | 9.5
EV/Sales
2.4 | 3.2
EV/FCF
negative
P/B
1.1
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$3.4b | $2.5b
EBITDA
$-456.4m | $-2.0b
EBIT
$-810.6m | $-2.1b
Net Income
$-402.8m | $-1.4b
Free Cash Flow
$-3.0b
Growth (TTM | estimate)
Revenue
7.0% | -20.8%
EBITDA
25.4% | -95.8%
EBIT
5.2% | -57.9%
Net Income
31.5% | -80.8%
Free Cash Flow
-208.7%
Margin (TTM | estimate)
Gross
84.2%
EBITDA
-13.6% | -77.3%
EBIT
-24.2%
Net
-12.0% | -55.2%
Free Cash Flow
-88.9%
Financial Health
Equity Ratio
86.2%
Return on Equity
-3.4%
ROCE
-3.5%
ROIC
-10.6%
Debt/Equity
0.0
More
EPS
$-1.7
FCF per Share
$-12.4
Short interest
6.8%
Employees
7k
Rev per Employee
$470.0k
Show more

Is BioNTech SE - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

BioNTech SE - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a BioNTech SE - ADR forecast:

20x Buy
74%
7x Hold
26%

Analyst Opinions

27 Analysts have issued a BioNTech SE - ADR forecast:

Buy
74%
Hold
26%

Financial data from BioNTech SE - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,357 3,357
7% 7%
100%
- Direct Costs 532 532
15% 15%
16%
2,825 2,825
6% 6%
84%
- Selling and Administrative Expenses 630 630
10% 10%
19%
- Research and Development Expense - -
-
-
-456 -456
25% 25%
-14%
- Depreciation and Amortization 354 354
46% 46%
11%
EBIT (Operating Income) EBIT -811 -811
5% 5%
-24%
Net Profit -403 -403
32% 32%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about BioNTech SE - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioNTech SE - ADR Stock News

Negative
Seeking Alpha
7 days ago
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...
Negative
Investors Business Daily
7 days ago
BioNTech stock skidded Wednesday after the Food and Drug Administration ended its broad authorization of Covid vaccines in the U.S.
Neutral
GlobeNewsWire
7 days ago
NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and olde...
More BioNTech SE - ADR News

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.

Head office Germany
CEO Ugur Sahin
Employees 6,772
Founded 2008
Website www.biontech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today